KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Receivables (2016 - 2025)

Arbutus Biopharma's Receivables history spans 15 years, with the latest figure at $905000.0 for Q3 2025.

  • For Q3 2025, Receivables fell 43.72% year-over-year to $905000.0; the TTM value through Sep 2025 reached $905000.0, down 43.72%, while the annual FY2024 figure was $2.4 million, 35.64% up from the prior year.
  • Receivables for Q3 2025 was $905000.0 at Arbutus Biopharma, down from $1.0 million in the prior quarter.
  • Across five years, Receivables topped out at $2.7 million in Q1 2023 and bottomed at $899000.0 in Q4 2021.
  • The 5-year median for Receivables is $1.7 million (2021), against an average of $1.7 million.
  • The largest annual shift saw Receivables soared 102.89% in 2023 before it tumbled 44.74% in 2025.
  • A 5-year view of Receivables shows it stood at $899000.0 in 2021, then skyrocketed by 50.39% to $1.4 million in 2022, then skyrocketed by 31.36% to $1.8 million in 2023, then soared by 35.64% to $2.4 million in 2024, then crashed by 62.43% to $905000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Receivables are $905000.0 (Q3 2025), $1.0 million (Q2 2025), and $1.2 million (Q1 2025).